Antihypertensive Drug Therapy

Article information

J Korean Med Assoc. 2003;46(8):753-759
Publication date (electronic) : 2003 August 31
doi : https://doi.org/10.5124/jkma.2003.46.8.753
Cardiovascular Center, Korea University College of Medicine, Anam Hospital, Korea. ymro@unitel.co.kr

Abstract

Aggressive treatment of hypertension has been proved to reduce morbidity and mortality. Data from recent clinical trials indicate that, for all stages of hypertension, the target BP should be a maximum BP <140/90 mmHg, with diastolic BP values as low as 70 mmHg. For patients with diabetes mellitus or chronic renal disease, this target value should be even lower, <130/80 mmHg. As significant morbidity and mortality attributable to hypertension occur in patients who are not diagnosed as having hypertension but whose blood pressure is in prehypertension range, 120~139/80~89 mmHg, lowering BP levels in this group is recommended as well, with lifestyle modification or drug therapy for some indicated patients being first-line therapy. Because controlling BP to <140/90 mmHg often requires use of two or more agents, selection of drugs for combination therapy should be based not only on antihypertensive efficacy, but also on compelling indications and tolerability of the regimens. This review presents the latest findings on the antihypertensive therapy and emphasizes the importance of decreasing BP per the JNC-7 guidelines.

References

1. Chobanian AV, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003. 2892560–2572.
2. Guideline Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003. 211011–1053.
3. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Westerling S, et al. for HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension : Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998. 3511755–1762.

Article information Continued

Figure 1

Figure 2

Figure 3

Table 1

Table 1

Table 2

Table 2

Table 3

Table 3

Table 4

Table 4

Table 5

Table 5